Enabling ICH Q10 Implementation—Part 1. Striving for Excellence by Embracing ICH Q8 and ICH Q9

References

1. 1.↵
   1. Deming W. E.

   Out of the Crisis, 1st ed.; MIT Press: Cambridge, MA, 2000; pp xiii.
2. 2.↵
   ICH. ICH Harmonised Tripartite Guideline: Pharmaceutical Quality System Q10; June, 2008.
3. 3.↵
   1. Friedman R. L.

   In Pharmaceutical Quality Systems: The US Perspective, ISPE/PDA Pharmaceutical Quality Systems ICH Q10, Brussels, Belgium, FDA, Ed. FDA: Brussels, Belgium, Oct 2011.
4. 4.↵
   Transfer Center for Technology Management at the University of St Gallen. Operational Excellence in the Pharmaceutical Industry. http://www.opexbenchmarking.com (accessed December 2012).
5. 5.↵
   1. Friedli T.

   Mastering Plant Complexity and the Impact of Operational Excellence. Presented at Global Pharma Manufacturing Summit 2012, Edison, NJ, November 26, 2012.
6. 6.↵
   ICH. ICH Harmonised Tripartite Guideline: Pharmaceutical Development Q8(R2). ICH, August, 2009.
7. 7.↵
   ICH. ICH armonised Tripartite Guideline: Quality Risk Management Q9. ICH, November, 2009.
8. 8.↵
   1. Abboud L.,
   2. Hensley S.

   New prescription for drugmakers: Update the plants. Wall Street J. 2003, September 3.
9. 9.↵
   Final Concept Paper on ICH Q8, Q9 and Q10. (ICH), November 2007.
10. 10.↵
    ICH. Final Concept Paper, Q8: Pharmaceutical Development, 8 October, 2003.
11. 11.↵
    1. Robert J. L.

    Introduction to ICH and the New Quality Paradigm. In Implementation of ICH Q8, Q9 and Q10: Q-IWG, Integrated Training Programme, Robert J. L., Ed. ICH: Washington DC, USA, November 2012.
12. 12.↵
    ICH. Final Concept Paper ICH Q9: Quality Risk Management. ICH, 11 November, 2003.
13. 13.↵
    ICH. Final Concept Paper Q10: Pharmaceutical Quality Systems. ICH, 10 November, 2005.
14. 14.↵
    ICH Q8, Q9 & Q10 Integrated Training Materials, 2010.
15. 15.↵
    ICH Quality Implementation Working Group on Q8, Q9 and Q10. Questions & Answers (R4) November, 2010.
16. 16.↵
    ICH Points To Consider (PtC), November, 2011.
17. 17.↵
    ASTM E2500–07 Standard Guide for Specification, Design, and Verification of Pharmaceutical and Biopharmaceutical Manufacturing Systems and Equipment. ASTM International: West Conshohocken, PA, 2003, 2007; DOI: 10.1520/E2500-07R12.
18. 18.↵
    International Society for Pharmaceutical Engineering (ISPE). Science and Risk-Based Approach for the Delivery of Facilities, Systems and Equipment June, 2011; p 120.
19. 19.↵
    FDA. Guidance for Industry, Process Validation: General Principles and Practices. Current Good Manufacturing Practices (CGMP) Revision 1; FDA, January, 2011; p 19.
20. 20.↵
    Dublin Institute of Technology, Pharmaceutical Regulatory Science Research Team website link http://www.dit.ie/chemistry/research/prst/.
21. 21.↵
    1. O'Donnell K.,
    2. Greene A.

    Failure modes: simple strategies for improving qualitative quality risk management exercises during qualification,validation and change control activities. J. Validation Technol. 2007, 13 (2), 100–112.

    OpenUrl
22. 22.↵
    1. O'Donnell K.,
    2. Zwitkovits M.,
    3. Greene A.,
    4. Calnan N.

    Quality risk management: putting GMP controls first. PDA J. Pharm. Sci. Technol. 2012, 66 (3), 243–261.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    1. O'Donnell K.,
    2. Greene A.

    A risk management solution designed to facilitate risk-based qualification, validation and change control activities within GMP and pharmaceutical regulatory compliance environments in the EU: Part I—Fundamental principles. J. GXP Compliance 2006, 10 (4), 12; O'Donnell, K., Greene, A. A risk management solution designed to facilitate risk-based qualification, validation and change control activities within GMP and pharmaceutical regulatory compliance environments in the EU: Part II.

    OpenUrl
24. 24.↵
    1. O'Donnell K.

    Strategies for addressing the problems of subjectivity and uncertainty in quality risk management exercises: Part I—The role of human heuristics. J. Validation Technol. 2010, 16 (3); O'Donnell, K. Strategies for addressing the problems of subjectivity and uncertainty in quality risk management exercises: Part II—Risk communication and perception. J. Validation Technol. 2010, 16 (4).
25. 25.↵
    1. Calnan N.,
    2. Greene A.

    Industry Benchmarking Poll: Quality Risk Management; http://www.dit.ie/chemistry/research/prst/researchpublications/.
26. 26.↵
    1. Calnan N.,
    2. Greene A.

    Pharmaceutical Industry Benchmarking: International Regulator Interviews on QRM Practices; http://www.dit.ie/chemistry/research/prst/researchpublications/.
27. 27.↵
    1. Friedman R. L.

    CDER Update, University of Georgia GMP Conference. March 15–17, 2011.
28. 28.↵
    1. O'Donnell K.

    Extract from an EU GMP Deficiency Report; 2011.
29. 29.↵
    1. Dean D.,
    2. Bruttin F.

    Risk and the economics of regulatory compliance. PDA J. Pharm. Sci. Technol. 1999, 54 (3), 253–263.

    OpenUrl
30. 30.↵
    1. Migliaccio G.

    Adapted from Migliaccio G. FDA will seek consultant help in implementing quality initiative. The GoldSheet 2002, 36 (9).
31. 31.↵
    1. Woodcock J.

    Reliable drug quality: an unresolved problem. PDA J. Pharm. Sci. Technol. 2012, 66 (3), 270–272.

    OpenUrlFREE Full Text
32. 32.↵
    1. Friedli T.,
    2. Basu P. K.,
    3. Gronauer T.,
    4. Werani J.

    The Pathway to Operational Excellence. 2010.
33. 33.↵
    ISPE, Parts 1, 2 & 3 Product Quality Lifecycle Implementation (PQLI) Guide Series. 2012.
34. 34.↵
    Transfer Center for Technology Management at the University of St Gallen. Operational Excellence in the Pharmaceutical Industry. http://www.opexbenchmarking.com (accessed December, 2012).
35. 35.↵
    Farlex. The Free Dictionary. Available at www.thefreedictionary.com.
36. 36.↵
    1. Poska R.

    Self inspection and its potential benefits via ICH Q9: an interview with Kevin O'Donnell, Ph.D., Irish Medicines Board. J. Validation Technol. 2010, 16 (2), 15.

    OpenUrl
37. 37.↵
    1. Nonaka I.,
    2. Toyama R.,
    3. Konno N.

    SECI, Ba and leadership: a unified model of dynamic knowledge creation. Long Range Planning 2000, 33 (1), 5–34.

    OpenUrlCrossRefWeb of Science